GlassScriptPhysician profile
Kobra Rezaei
NPI 1326622416
$1,308.69
in general payments reported to CMS, 2019-2025
12 companies · $213 in 2025
The $213 reported for 2025 was more than what a typical Adult Health (Nurse Practitioner) provider received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $88.12 · 2022: $315 · 2023: $438 · 2024: $255 · 2025: $213.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $905.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $905.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $376.63 | 2023-2024 | Interstim |
| Sumitomo Pharma America, INC. | $322.50 | 2023-2025 | Gemtesa |
| Urovant Sciences INC | $309.69 | 2021-2022 | |
| Teleflex LLC | $94.15 | 2022-2025 | Urolift, Barrigel |
| Boston Scientific Corporation | $43.27 | 2025 | Spaceoar Vue System - 10ml, Rezum Generator |
| Acerus Pharmaceuticals Corporation | $41.90 | 2021-2022 | |
| 180 Medical, INC. | $29.07 | 2025 | |
| Pacira Pharmaceuticals Incorporated | $23.61 | 2022 | |
| Janssen Biotech, INC. | $19.54 | 2025 | Erleada |
| Becton, Dickinson and Company | $18.42 | 2025 | Magic3 Go Intermittent Urinary Catheter |
| Novartis Pharmaceuticals Corporation | $17.87 | 2025 | |
| Tolmar Pharmaceuticals, INC. | $12.04 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kobra Rezaei listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.